Squarepoint Ops LLC Relmada Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.93 - $4.94 $127,712 - $215,324	-43,588 Reduced 55.17%	35,425 $106,000
Q1 2024 May 15, 2024	BUY	$3.1 - $6.8 $17,294 - $37,937	5,579 Added 7.6%	79,013 $367,000
Q4 2023 Feb 14, 2024	SELL	$2.45 - $4.22 $13,685 - $23,572	-5,586 Reduced 7.07%	73,434 $304,000
Q2 2023 Aug 14, 2023	BUY	$2.22 - $3.54 $175,424 - $279,730	79,020 New	79,020 $194,000
Q4 2022 Feb 14, 2023	BUY	$2.17 - $35.84 $76,559 - $1.26 Million	35,281 New	35,281 $123,000
Q1 2021 May 17, 2021	SELL	$31.52 - $39.28 $224,737 - $280,066	-7,130 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$29.88 - $39.8 $213,044 - $283,774	7,130 New	7,130 $229,000
Q3 2020 Nov 16, 2020	SELL	$34.42 - $43.78 $279,008 - $354,880	-8,106 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$31.59 - $49.98 $256,068 - $405,137	8,106 New	8,106 $363,000
Q1 2020 May 15, 2020	SELL	$23.78 - $50.12 $212,070 - $446,970	-8,918 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$10.1 - $47.18 $90,071 - $420,751	8,918 New	8,918 $348,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.